PARA IV CHALLENGES BLEED RANBAXY AS MULTINATIONALS SUE ON 11 MOLECULES

India's leading drug maker Ranbaxy Laboratories Ltd. is facing the legal music from a dozen odd multinational companies on at least 11 of its generic molecules in its pursuit to conquer the global generic market through the Para IV challenge route. This includes legal battles with companies like Abbott, AztraZeneca, Aventis Pharma, Wyeth, Scherer, Cardinal Health, Cephalon Inc, GSK, Astella Pharma, Takeda and the much-hyped duel with Pfizer on Lipitor in 16 jurisdictions around the world.

Pharmabiz (http://pharmabiz.com/article/detnews.asp?articleid=34370§ionid=)